Pharmacokinetics of isoniazid: The good, the bad, and the alternatives
- 1 May 2019
- journal article
- conference paper
- Published by Elsevier in Tuberculosis
- Vol. 116, S66-S70
Abstract
No abstract availableKeywords
Funding Information
- Welch Foundation
- U.S. Department of Energy
This publication has 48 references indexed in Scilit:
- Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and ManagementJournal of Clinical and Experimental Hepatology, 2013
- NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapyEuropean Journal of Clinical Pharmacology, 2012
- A Novel Metabolite of Antituberculosis Therapy Demonstrates Host Activation of Isoniazid and Formation of the Isoniazid-NAD+AdductAntimicrobial Agents and Chemotherapy, 2012
- Mode of Binding of the Tuberculosis Prodrug Isoniazid to Heme PeroxidasesJournal of Biological Chemistry, 2010
- Microbial NAD Metabolism: Lessons from Comparative GenomicsMicrobiology and Molecular Biology Reviews, 2009
- The Role of Transporters in the Pharmacokinetics of Orally Administered DrugsPharmaceutical Research, 2009
- Transfer of isoniazid from circulation to breast milk in lactating women on chronic therapy for tuberculosisBritish Journal of Clinical Pharmacology, 2007
- Exacerbation of isoniazid induced peripheral neuropathy by pyridoxine.Thorax, 1990
- Clinical Pharmacokinetics of the Antituberculosis DrugsClinical Pharmacokinetics, 1984
- Clinical Pharmacokinetics of IsoniazidClinical Pharmacokinetics, 1979